tiprankstipranks
Bristol-Myers Squibb (BMY)
NYSE:BMY
US Market
BMY
Bristol-Myers Squibb
RESEARCH TOOLSreports
Want to see BMY full AI Analyst Report?

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

12,055 Followers
See the Price Targets and Ratings of:

BMY Analyst Ratings

Moderate Buy
20Ratings
Moderate Buy
7 Buy
12 Hold
1 Sell
Based on 20 analysts giving stock ratings to
Bristol-Myers
Squibb
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BMY Stock 12 Month Forecast

Average Price Target

$62.28
▲(3.50% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is $62.28 with a high forecast of $75.00 and a low forecast of $40.00. The average price target represents a 3.50% change from the last price of $60.17.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"$39","76":"$76","48.25":"$48.3","57.5":"$57.5","66.75":"$66.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.27777777777778,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$62.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,48.25,57.5,66.75,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.1,62.16923076923077,63.23846153846154,64.3076923076923,65.37692307692308,66.44615384615385,67.51538461538462,68.58461538461539,69.65384615384616,70.72307692307692,71.79230769230769,72.86153846153846,73.93076923076923,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.1,61.190598290598295,61.28119658119658,61.371794871794876,61.46239316239316,61.552991452991456,61.64358974358974,61.73418803418804,61.824786324786324,61.91538461538462,62.005982905982904,62.0965811965812,62.187179487179485,{"y":62.27777777777778,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.1,59.47692307692308,57.853846153846156,56.23076923076923,54.60769230769231,52.98461538461539,51.36153846153846,49.738461538461536,48.11538461538461,46.49230769230769,44.86923076923077,43.246153846153845,41.62307692307692,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.107,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.249,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.468,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.248,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.527,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.768,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.067,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.109,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.765,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.319,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.703,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$75.00Average Price Target$62.28Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on BMY
David Amsellem
Piper Sandler
Piper Sandler
$75
Buy
24.65%
Upside
Reiterated
04/23/26
Piper Sandler Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
Bernstein Analyst forecast on BMY
Courtney Breen
Bernstein
Bernstein
$58
Hold
-3.61%
Downside
Reiterated
04/21/26
Bernstein Remains a Hold on Bristol-Myers Squibb (BMY)
Barclays Analyst forecast on BMY
Emily Field
Barclays
Barclays
$75
Buy
24.65%
Upside
Reiterated
04/21/26
Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
Wells Fargo Analyst forecast on BMY
Mohit Bansal
Wells Fargo
Wells Fargo
$60
Hold
-0.28%
Downside
Assigned
04/13/26
Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
RBC Capital Analyst forecast on BMY
Trung Huynh
RBC Capital
RBC Capital
$60
Hold
-0.28%
Downside
Reiterated
04/10/26
Bristol-Myers Squibb (BMY) Gets a Hold from RBC Capital
Bank of America Securities Analyst forecast on BMY
Jason Gerberry
Bank of America Securities
Bank of America Securities
$68→$67
Buy
11.35%
Upside
Reiterated
04/09/26
Bristol Myers price target lowered to $67 from $68 at BofABristol Myers price target lowered to $67 from $68 at BofA
Cantor Fitzgerald Analyst forecast on BMY
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$45→$54
Hold
-10.25%
Downside
Reiterated
04/08/26
Bristol Myers price target raised to $54 from $45 at Cantor FitzgeraldBristol Myers price target raised to $54 from $45 at Cantor Fitzgerald
Guggenheim Analyst forecast on BMY
Seamus Fernandez
Guggenheim
Guggenheim
$72
Buy
19.66%
Upside
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Vor Biopharma (NASDAQ: VOR) and Bristol-Myers Squibb (NYSE: BMY)
Scotiabank Analyst forecast on BMY
Louise Chen
Scotiabank
Scotiabank
$60
Hold
-0.28%
Downside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), IDEAYA Biosciences (NASDAQ: IDYA) and Bristol-Myers Squibb (NYSE: BMY)
Erste Group Analyst forecast on BMY
Unknown Analyst
Erste Group
Not Ranked
Erste Group
―
Hold
―
Reiterated
04/01/26
Bristol-Myers Squibb (BMY) Gets a Hold from Erste Group
HSBC Analyst forecast on BMY
Rajesh Kumar
HSBC
HSBC
$53→$60
Hold
-0.28%
Downside
Reiterated
03/17/26
Bristol Myers price target raised to $60 from $53 at HSBCBristol Myers price target raised to $60 from $53 at HSBC
Goldman Sachs Analyst forecast on BMY
Asad Haider
Goldman Sachs
Goldman Sachs
$59.71→$61
Hold
1.38%
Upside
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: ProKidney (NASDAQ: PROK), Molecular Partners (NASDAQ: MOLN) and Bristol-Myers Squibb (NYSE: BMY)
Citi Analyst forecast on BMY
Geoff Meacham
Citi
Citi
$64
Hold
6.37%
Upside
Reiterated
03/10/26
Citi Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
William Blair Analyst forecast on BMY
Matt Phipps
William Blair
William Blair
―
Hold
―
Reiterated
03/09/26
Balanced Outlook on BMY: Positive Mezigdomide Phase III Data Support CELMoD Platform, but Long-Term Execution Risks Warrant Hold Rating
UBS Analyst forecast on BMY
Michael Yee
UBS
UBS
$65→$70
Buy
16.34%
Upside
Assigned
03/06/26
Bristol Myers price target raised to $70 from $65 at UBSBristol Myers price target raised to $70 from $65 at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on BMY
David Amsellem
Piper Sandler
Piper Sandler
$75
Buy
24.65%
Upside
Reiterated
04/23/26
Piper Sandler Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
Bernstein Analyst forecast on BMY
Courtney Breen
Bernstein
Bernstein
$58
Hold
-3.61%
Downside
Reiterated
04/21/26
Bernstein Remains a Hold on Bristol-Myers Squibb (BMY)
Barclays Analyst forecast on BMY
Emily Field
Barclays
Barclays
$75
Buy
24.65%
Upside
Reiterated
04/21/26
Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
Wells Fargo Analyst forecast on BMY
Mohit Bansal
Wells Fargo
Wells Fargo
$60
Hold
-0.28%
Downside
Assigned
04/13/26
Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
RBC Capital Analyst forecast on BMY
Trung Huynh
RBC Capital
RBC Capital
$60
Hold
-0.28%
Downside
Reiterated
04/10/26
Bristol-Myers Squibb (BMY) Gets a Hold from RBC Capital
Bank of America Securities Analyst forecast on BMY
Jason Gerberry
Bank of America Securities
Bank of America Securities
$68→$67
Buy
11.35%
Upside
Reiterated
04/09/26
Bristol Myers price target lowered to $67 from $68 at BofABristol Myers price target lowered to $67 from $68 at BofA
Cantor Fitzgerald Analyst forecast on BMY
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$45→$54
Hold
-10.25%
Downside
Reiterated
04/08/26
Bristol Myers price target raised to $54 from $45 at Cantor FitzgeraldBristol Myers price target raised to $54 from $45 at Cantor Fitzgerald
Guggenheim Analyst forecast on BMY
Seamus Fernandez
Guggenheim
Guggenheim
$72
Buy
19.66%
Upside
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Vor Biopharma (NASDAQ: VOR) and Bristol-Myers Squibb (NYSE: BMY)
Scotiabank Analyst forecast on BMY
Louise Chen
Scotiabank
Scotiabank
$60
Hold
-0.28%
Downside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), IDEAYA Biosciences (NASDAQ: IDYA) and Bristol-Myers Squibb (NYSE: BMY)
Erste Group Analyst forecast on BMY
Unknown Analyst
Erste Group
Not Ranked
Erste Group
―
Hold
―
Reiterated
04/01/26
Bristol-Myers Squibb (BMY) Gets a Hold from Erste Group
HSBC Analyst forecast on BMY
Rajesh Kumar
HSBC
HSBC
$53→$60
Hold
-0.28%
Downside
Reiterated
03/17/26
Bristol Myers price target raised to $60 from $53 at HSBCBristol Myers price target raised to $60 from $53 at HSBC
Goldman Sachs Analyst forecast on BMY
Asad Haider
Goldman Sachs
Goldman Sachs
$59.71→$61
Hold
1.38%
Upside
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: ProKidney (NASDAQ: PROK), Molecular Partners (NASDAQ: MOLN) and Bristol-Myers Squibb (NYSE: BMY)
Citi Analyst forecast on BMY
Geoff Meacham
Citi
Citi
$64
Hold
6.37%
Upside
Reiterated
03/10/26
Citi Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
William Blair Analyst forecast on BMY
Matt Phipps
William Blair
William Blair
―
Hold
―
Reiterated
03/09/26
Balanced Outlook on BMY: Positive Mezigdomide Phase III Data Support CELMoD Platform, but Long-Term Execution Risks Warrant Hold Rating
UBS Analyst forecast on BMY
Michael Yee
UBS
UBS
$65→$70
Buy
16.34%
Upside
Assigned
03/06/26
Bristol Myers price target raised to $70 from $65 at UBSBristol Myers price target raised to $70 from $65 at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

3 Months
xxx
Success Rate
12/14 ratings generated profit
86%
Average Return
+10.59%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +10.59% per trade.
1 Year
Srikripa DevarakondaTruist Financial
Success Rate
12/14 ratings generated profit
86%
Average Return
+14.69%
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +14.69% per trade.
2 Years
xxx
Success Rate
14/14 ratings generated profit
100%
Average Return
+26.50%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +26.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMY Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
22
24
24
16
12
Hold
40
37
33
27
24
Sell
5
5
4
2
1
Strong Sell
0
0
0
0
0
total
67
66
61
45
37
In the current month, BMY has received 12 Buy Ratings, 24 Hold Ratings, and 1 Sell Ratings. BMY average Analyst price target in the past 3 months is 62.28.
Each month's total comprises the sum of three months' worth of ratings.

BMY Financial Forecast

BMY Earnings Forecast

Next quarter’s earnings estimate for BMY is $1.42 with a range of $1.23 to $1.53. The previous quarter’s EPS was $1.26. BMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.
Next quarter’s earnings estimate for BMY is $1.42 with a range of $1.23 to $1.53. The previous quarter’s EPS was $1.26. BMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Sales Forecast

Next quarter’s sales forecast for BMY is $10.93B with a range of $10.63B to $11.42B. The previous quarter’s sales results were $12.50B. BMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.
Next quarter’s sales forecast for BMY is $10.93B with a range of $10.63B to $11.42B. The previous quarter’s sales results were $12.50B. BMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Stock Forecast FAQ

What is BMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 62.28.
    What is BMY’s upside potential, based on the analysts’ average price target?
    Bristol-Myers Squibb has 3.50% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BMY a Buy, Sell or Hold?
          Bristol-Myers Squibb has a consensus rating of Moderate Buy which is based on 7 buy ratings, 12 hold ratings and 1 sell ratings.
            What is Bristol-Myers Squibb’s price target?
            The average price target for Bristol-Myers Squibb is 62.28. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $75.00 ,the lowest forecast is $40.00. The average price target represents 3.50% Increase from the current price of $60.17.
              What do analysts say about Bristol-Myers Squibb?
              Bristol-Myers Squibb’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of BMY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.